News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amorfix Life Sciences Ltd. Announces Breakthrough Scientific Discovery and Provides Update for Its Ovarian Cancer Therapeutic Antibody Program


4/9/2013 10:39:00 AM

TORONTO, April 9, 2013 /CNW/ - Amorfix Life Sciences announced today it has completed a study that shows that the treatment of cancer cells with chemotherapeutic agents increases the amount of misfolded prion protein at the cell surface, and the subsequent binding of anti-prion protein antibodies. The increased expression is specific to tumor cells and is not seen on normal ovarian cells. In addition, the Company reports the completion of the first in a series of studies with its anti-misfolded prion protein antibody in animal models of ovarian cancer with promising preliminary results on reducing tumor volume.

Read at Canada NewsWire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES